Albert Selva-O'Callaghan, MD, PhD
Affiliations: | Internal Medicine | Vall d'Hebron Institut de Recerca |
Google:
"Albert Selva-O'Callaghan"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Loganathan A, Zanframundo G, Yoshida A, et al. (2024) Agreement between local and central anti-synthetase antibodies detection: results from the Classification Criteria of Anti-Synthetase Syndrome project biobank. Clinical and Experimental Rheumatology. 42: 277-287 |
| Torres-Ruiz J, Pinal-Fernandez I, Selva-O'Callaghan A, et al. (2024) Nailfold capillaroscopy findings of a multicentric multi-ethnic cohort of patients with idiopathic inflammatory myopathies. Clinical and Experimental Rheumatology. 42: 367-376 |
| Pinal-Fernandez I, Muñoz-Braceras S, Casal-Dominguez M, et al. (2024) Pathogenic autoantibody internalization in myositis. Medrxiv : the Preprint Server For Health Sciences |
| Muñoz-Braceras S, Pinal-Fernandez I, Casal-Dominguez M, et al. (2023) Identification of Unique microRNA Profiles in Different Types of Idiopathic Inflammatory Myopathy. Cells. 12 |
| Guerra NL, Matas-García A, Serra-García L, et al. (2023) Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature. Autoimmunity Reviews. 22: 103375 |
| Pinal-Fernandez I, Milisenda JC, Pak K, et al. (2023) Transcriptional derepression of CHD4/NuRD-regulated genes in the muscle of patients with dermatomyositis and anti-Mi2 autoantibodies. Annals of the Rheumatic Diseases |
| Pinal-Fernandez I, Quintana A, Milisenda JC, et al. (2023) Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis. Annals of the Rheumatic Diseases |
| Casal-Dominguez M, Pinal-Fernandez I, Pak K, et al. (2023) Coordinated local RNA overexpression of complement induced by interferon gamma in myositis. Scientific Reports. 13: 2038 |
| Selva-O'Callaghan A, Trallero-Araguás E, Ros J, et al. (2022) Management of Cancer-Associated Myositis. Current Treatment Options in Rheumatology. 8: 91-104 |
| Hosono Y, Sie B, Pinal-Fernandez I, et al. (2022) Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1γ autoantibodies. Annals of the Rheumatic Diseases |